Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, diagnostic test maker Meridian Bioscience (VIVO) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Meridian and see what CAPS investors are saying about the stock right now.
Meridian facts
|
Headquarters (founded) |
Cincinnati (1976) |
|
Market Cap |
$886.4 million |
|
Industry |
Healthcare supplies |
|
Trailing-12-Month Revenue |
$173.5 million |
|
Management |
CEO John Kraeutler (since 2008) CFO Melissa Lueke (since 2001) |
|
Return on Equity (average, past 3 years) |
20.9% |
|
Cash/Debt |
$31.6 million / $0 |
|
Dividend Yield |
3.6% |
|
Competitors |
Abbott Labs |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 475 members who have rated Meridian believe the stock will outperform the S&P 500 going forward.
A few months ago, one of those Fools, TempAllegro, succinctly summed up the bull case for our community:
[Meridian] makes a range of diagnostic tests for foodborne, parasitic, viral, and other diseases that you can do at home. ...
With increasing threats to the food supply and environmental concerns such as lack of proper water for both humans and livestock, these tests will be both helpful and in greater demand in coming years.
Add to that its great balance sheet -- currently with zero debt and current ratio of over 5, plus high insider ownership, generous dividend, and 5-year projected growth in the mid-teens, and we have an excellent addition to anyone's health-oriented portfolio.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
